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Abstract
Background: Paravalvular leakage (PVL) is a known complication of transcatheter aortic valve implantation (TAVI)
and is associated with poor outcome. Besides balloon-post-dilatation, valve-in-valve (ViV) procedures can be taken
into consideration to control this complication. Herein we present initial experience with use of the latest
generation balloon-expandable Edwards Sapien 3® (S3) transcatheter heart valve (THV) for treatment of failing THVs.
Methods: Between 01/2014 and 12/2014 three patients (two male, age: 71–80 y, log EUROScore I: 11.89 – 32.63)
with failing THVs were refered to our institution for further treatment. THV approach with secondary implantation of
an S3 was chosen after mutual agreement of the local interdisciplinary heart team at an interval of 533–1119 days
from the index procedure. The performed procedures consisted of: S3 in Sapien XT, JenaValve and CoreValve.
Results: Successful transfemoral implantation with significant reduction of PVL was achieved in all cases. No
intraprocedural complications occured regarding placement of the S3 with a postprocedural effective orifice area
(EOA) of 1.5–2.5 cm2 and pressure gradients of max/mean 14/6–36/16 mmHg. 30-day mortality was 0 %. At the
latest follow-up of 90–530 days, all patients are alive and well with satisfactory THV function. Regarding VARC-2
criteria one major bleeding and one TIA was reported.
Conclusions: In the instance of moderate or severe aortic regurgitation after TAVI, S3 ViV deployment is an
excellent option to reduce residual regurgitation to none or mild. For further assertions concerning functional
outcomes long-term results have to be awaited.
Keywords: Aortic valve disease, Aortic valve stenosis, Paravalvular leak, Percutaneous valve therapy, Structural heart
disease intervention, TAVI, THV
Background
Transcatheter aortic valve implantation (TAVI) has found
widespread acceptance as alternative to surgical aortic
valve replacement (SAVR) over the last decade. Through
introduction of transcatheter heart valves (THV) into clin-
ical daily routine, mortality of inoperable or high-risk pa-
tients was significantly reduced compared to medical
therapy [1, 2]. In 2012, the PARTNER trial presented data
which showed comparable results of the first generation
Edwards Sapien THV (Edwards Lifesciences Co., Irvine,
CA, USA) and SAVR for severe aortic stenosis in high-risk
patients regarding mortality, reduction in symptoms and
valve hemodynamics [3]. Despite introduction of a wide
variety of THVs into the medical sector, with largely favor-
able results [4, 5] and improved delivery systems, imaging
or access site techniques [6–8], one major problem of
THVs remains paravalvular leakage (PVL). PVL has a sig-
nificantly higher incidence following TAVI compared to
SAVR and leads to increased mortality if grade of PVL is ≥
moderate (2-year mortality of 30 % in mild aortic
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regurgitation, 40 % in moderate, 3-year mortality of 60 %
in severe aortic regurgitation) [9, 10]. For failing THVs,
different strategies had to be developed to control these
complications, avoid acute hemodynamic compromise
and preserve therapeutic benefits of the TAVI procedure.
Besides balloon-post-dilatation, valve-in-valve (ViV) pro-
cedures can be taken into consideration [11, 12]. It was
shown for the Edwards Sapien XT THV, that it is suitable
for ViV procedures in cases of failing CoreValve THV
(Medtronic Ltd., Dublin, IRL) with relevant PVL [13].
To date only one case report exists regarding suitabil-
ity of the Edwards Sapien 3 (S3) THV for ViV treat-
ment of a failing CoreValve THV [14]. In this case
series, we report initial experience with the S3 for




Routine preprocedural diagnostic work-up included trans-
thoracic (TTE) and transesophageal echocardiography
(TEE), coronary angiogram, as well as contrast-enhanced,
electrocardiogram-gated multislice computed tomography
(CT) scans. Decision for ViV procedure was made after
mutual agreement of the local interdisciplinary heart
team. All described procedures were performed in a hy-
brid operating room by an interdisciplinary team consist-
ing of cardiac surgeons and interventional cardiologists.
Patients
Three procedures were performed using the S3 THV for
failing THV between 01/2014 and 12/2014. All patients
presented with prohibitive operative risk for SAVR with a
mean logistic European System for Cardiac Operative Risk
Evaluation I (log EuroSCORE) of 11.89 – 32.63 and log
EuroSCORE II of 2.33–19.14. Two of them were male and
rang of age was 71–80 years. In one patient scheduled
ViV procedure was the third interventional cardiac pro-
cedure with a status post CoreValve and Mitraclip im-
plantation. All patients suffered from atrial fibrillation.
Detailed clinical data are summarized in Table 1. All pro-
cedures which were carried out are in compliance with
the Helsinki Declaration.
Table 1 Clinical baseline data and initial TAVI procedure information
Patient no. 1 Patient no. 2 Patient no. 3
Age (y) 80 78 71
Gender female male male
BMI (kg/m2) 46.6 21 21.6
Comorbidities AF, RI, osteoporosis, s/p TKA both
sides, AH, NIDDM
AF, 1 VD, prostate cancer, s/p rectum
cancer, COPD IV, AH
s/p DES in LAD, 3VD, s/p
Mitraclip, AF
logEuroSCORE I (%) 23.92 11.89 32.63
logEuroSCORE II (%) 5.54 2.33 19.14
STS PROM (%) 4.69 3.78 2.744
NYHA III III IV
TTE before index procedure
LVEF (%) 60 50 30
EOA (cm2) 0.9 0.7 0.9
Gradient max/mean (mmHg) 82/41 90/52 30/12
Valve insufficiency none none none
Index procedure
Implanted THV, size (mm) Edwards Sapien XT, 26 JenaValve, 27 CoreValve, 29
Symptoms after index procedure syncope, dyspnea dyspnea dyspnea
Time to 2nd procedure (d) 1119 533 814
TTE after index procedure
EOA (cm2) / 1.9 2.8
Gradient max/mean (mm Hg) / 27/10 15/9
Valve insufficiency mild mild mild
Y years; BMI body mass index; logEuroSCORE logistic European System for Cardiac Operative Risk Evaluation; STS PROM Society of Thoracic Surgeons Predicted Risk
of Mortality; NYHA New York Heart Association; TTE transthoracic echocardiography; LVEF left ventricular ejection fraction; EOA effective orifice area; TAVI
transcatheter aortic valve implantation; THV transcatheter heart valve; AF atrial fibrillation; RI renal insufficiency; TKA total knee arthroplasty; AH arterial
hypertension; NIDDM non insulin dependent diabetes mellitus; VD vessel disease; s/p status post; COPD chronical obstructive pulmonal disease; PVL paravalvular
leakage; SD standard deviation
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Initial TAVI procedure
Initial TAVI procedures were performed via transfemoral
(tf ) access in two cases (Edwards Sapien XT, CoreValve)
and via transapical (ta) access in one case (JenaValve).
Implantation was performed due to severe aortic sten-
osis in all cases. TTE prior to discharge after index pro-
cedure presented mild PVL in all cases with sufficient
EOA and pressure gradients and patients were dis-
charged with improved NYHA functional class of ≤ II.
Index procedural data are summarized in Table 1.
At an interval of 533–1119 days, patients were readmit-
ted with acute exacerbation of dyspnea or status post
syncope. In patient 1 serial TTE examination due to re-
current cardiac decompensation presented severe PVL
from one year after the index procedure, which was reluc-
tantly observed and re-intervention was refused due to
the high-risk profile. In the other two patients first detec-
tion of moderate or severe PVL of the THV led to imme-
diate reinterventions. Severe PVL was demonstrated in all
patients on TTE at time of admission. Detailed echocardi-
ography data before ViV procedure are shown in Table 2.
Valve-in-Valve implantation procedure
Due to echocardiographic findings and reduced clinical
status in all three cases, repeat TAVI was indicated fol-
lowing heart team consensus. Sizing was conducted by
reference to CT of the index procedures to reduce
radiation exposure with effective annulus sizes (based on
CTeff = 2 × √(circumferential area/π) of 23 mm for the
Sapien XT patient, 29 mm for the JenaValve patient and
24 mm for the CoreValve patient.
Due to adequate peripheral vasculature as assessed by
reconstruction of the planning CT, all procedures were
performed via percutaneous tf access following standard
procedural protocol. After insertion of a vascular closure
system (ProStar XL Percutaneous Vascular Surgical Sys-
tem®, Abbott Vascular, Santa Clara, CA, USA) in the
right femoral artery and placement of a pacemaker lead
in the RV via the right jugular vein, a guide wire was ad-
vanced retrogradely across the THV into the LV. Subse-
quently the S3 THV was deployed into the THV in a
phase of rapid ventricular pacing, with prior positioning
of the radio-opaque marker at the height of native the
aortic annulus. Intraprocedurally, TEE and aortic root
angiography as well as invasive pressure measurements
were performed to document adequate THV function.
In two cases a cerebral protection system (Claret Med-
ical, Inc., Santa Rosa, CA, USA) was placed via the right
brachial artery into the brachiocephalic trunk and left
common carotid artery to protect against possible distal
embolization. Intraprocedural data are summarized in
Table 2.
Events were recorded according to Valve Academic
Research Consortium 2 (VARC-2) standard criteria.
Table 2 Preprocedural and postprocedural echocardiography data, Intraprocedural information
Patient no. 1 Patient no. 2 Patient no. 3
TTE/TEE before 2nd procedure
LVEF (%) 60 50 30
Gradient max/mean (mm Hg) 18/9 24/12 15/12
EOA (cm2) 1.7 2.2 2.3
Valve insufficiency severe moderate-severe severe
ViV procedure Edwards Sapien XT JenaValve CoreValve
Edwards Sapien 3 size (mm) 26 29 29
Procedure time (mm) 95 100 180
Fluoroscopy time (min) 10 11 20
Contrast agent (mL) 121 125 174
TTE discharge
LVEF (%) 60 50 30
EOA (cm2) 1.5 2.5 2.5
Gradient max/mean (mm Hg) 36/16 17/9 14/6
Paravalvular leakage none trace trace
ICU stay (d) 2 1 1
Hospital stay (d) 10 8 20
VARC-2 events at 30 days Major bleeding None TIA
TTE transthoracic echocardiography; TEE transesophageal echocardiography; LVEF left ventricular ejection fraction; ViV valve-in-valve; mm millimeter; min minutes;
mL milliliter; EOA effective orifice area; ICU intensive care unit; VARC-2 Valve academic research consortium; TIA transitory ischemic attack; SD standard deviation
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Results
All patients were successfully implanted with a S3 THV
for PVL of previous implanted THV without major com-
plications such as stroke, myocardial infarction due to
coronary obstruction or significant aortic regurgitation.
Immediate intraprocedural invasive mean pressure mea-
surements showed decline of 10 mmHg to 5 mmHg for
S3 in Sapien XT, 10 mmHg to 4 mmHg for S3 in Jena-
valve and 21 mmHg to 12 mmHg for S3 in CoreValve.
In all patients severity of PVL was reduced to none/trace
as documented by intraprocedural TEE, angiography
and invasive measurements of hemodynamics. Findings
were confirmed by TTE at the time of discharge. Echo-
cardiography results are summarized in Table 2.
Figure 1 shows development of EOA, PVL grade and
max/mean pressure gradient over time from initial
evaluation until discharge after second procedure. One
patient showed slightly decrease of EOA without result-
ing in clinical symptoms such as dyspnea after the pro-
cedure. In all other patients increase in EOA was
achieved. Accordingly in TTE prior to discharge mean
pressure gradients were lowered in two patients but peak
pressure gradients increased in two patients.
Intraprocedural angiographies are depicted in Fig. 2.
Three patients presented PVL two to three years after
the index procedure and were implanted with an S3
electively with a hospital stay of 8–20 d and an intensive
care unit stay of 1–2 d.
According to VARC-2 criteria one major bleeding (ac-
cess site hematoma requiring transfusion of two units of
red blood cells) and one transient ischemic attack (TIA)
was observed. TIA became apparent in sensory loss of
the right hand of a patient with pre-existing severe sten-
osis of the left internal carotid artery. Symptoms sub-
sided after 12 h. None of the patients had acute kidney
injury or need of renal replacement therapy. All patients
were alive at 30 days of follow-up and at the time of 90–
530 days after the procedure, respectively.
Discussion
Reasons for failing THV differ. Eccentric annulus calcifi-
cation with incomplete stent expansion, aortic or
Fig. 1 EOA, PVL and max/mean pressure gradients. Graphical overview of development of EOA (a), grade of regurgitation (b) and max/mean
pressure gradients (c; d) from initial echocardiography before index procedure to discharge after valve-in-valve procedure with the Edwards
Sapien 3®. (EOA- effective orifice area; TAVI- transcatheter aortic valve implantation)
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ventricular malpositioning, or malsizing of THV are
among the most common causes for PVL [15–17]. Re-
gardless of cause, PVL is responsible for inferior acute
and long-term clinical outcomes.
In this work, we presented initial experience with the
S3 for ViV therapy of different failing THVs in cases of
relevant recurring PVL. ViV procedures were performed
safely and reliably for severe PVL in the Sapien XT, the
JenaValve and the CoreValve. In self-expandable THV,
such as the CoreValve and the JenaValve, radial forces
might be too weak in particular cases for full expansion
of the stent. When suboptimal expansion occurs ballon-
post-dilatation is usually performed. In our cases
balloon-post-dilatation was performed at the time of the
index procedure but severe PVL still recurred. PVL was
increasing over a period of two to three years in these
THV to an unacceptable level. As illustrated in Fig. 2,
ViV procedures using the S3 led to further expansion of
the stent of the initially implanted self-expandable THV
and therefore to reduction of PVL to none/trace. Im-
plantation of the S3 at the level of the aortic annulus
was suitable and led to satisfying hemodynamic
outcome.
The hemodynamic performance of the S3 in Sapien
XT showed inferiority resulting in EOA of 1.5 cm2 and
max/mean pressure gradient of 36/16 mmHg without
Fig. 2 Angiographies of valve-in-valve procedures with the Sapien 3® into Sapien XT®, JenaValve® and CoreValve®. Column (a) with
angiography of severely regurgitant Sapien XT valve without (1) and with contrast agent (2), deployment of Sapien 3 (3) and final angiography
without paravalvular or transvalvular leakage (4) Column (b) presents angiography of regurgitant JenaValve without (1) and with contrast agent
(2), deployment of Sapien 3 (3) and final angiography with trace paravalvular leakage and no transvalvular leakage (4) Column (c) with
angiography of regurgitant CoreValve without (1) and with contrast agent (2), deployment of Sapien 3 (3) and final angiography with trace
para- and no transvalvular leakage (4)
Table 3 Overview of native aortic annulus, initial and second THV diameter and area
Patient no. 1 Patient no. 2 Patient no. 3
Initial annular diametera (mm) 25.3 26.2 25.6
Initial annular area (mm2) 490.3 620.1 530.7
Initial THV, size (mm) Edwards Sapien XT, 26 JenaValve, 27 CoreValve, 29
Covered annulus area of initial THVb (mm2) 415–530 / 415.5–572.6
Covered annulus diameter of initial THVb (mm) 23–26 25–27 23–27
Sapien 3 size (mm) 26 29 29
Covered annulus area of implanted Sapien 3b (mm2) 430–546 540–683 540–683
Covered annulus diameter of implanted Sapien 3b (mm) 23.4–26.4 26.2–29.5 26.2–29.5
a based on CTeff = 2 × √(circumferential area/π)
b according to information provided by manufacturer
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leading to clinical inferiority. This might be due to im-
plantation of both valves at the height of the aortic an-
nulus and/or the stout stent profile. It might be
beneficial, in terms of hemodynamics, to implant THV
with supraannular anchoring in those patients to avoid
elevated pressure gradients and reduced EOA.
Reasons for failing of initially implanted THV, in terms
of PVL, remained unclear. All patients presented only
mild PVL in TTE prior to discharge after index procedure
without elevated pressure gradients or inadequate EOA.
Moreover all initial implanted THV covered the native
aortic annulus area and diameter measured prior to the
first procedure. Nevertheless, THV used for ViV proce-
dures covered larger aortic annulus diameter and areas.
For detailed diameter and area values see Table 3.
Thus, reasons for failing are only speculative. Pos-
sibly, intra- and postprocedural underestimation of
PVL in TTE and TEE examinations, stent-recoiling or
measuring errors in MSCT prior to the first TAVI
might have been responsible for development of se-
vere regurgitation.
Conclusions
In conclusion, the S3 was well suitable for ViV therapy
in failing THV. Adequate hemodynamic results were ob-
tained. For further assertions concerning functional out-
comes long-term results have to be awaited.
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